Market capitalization

Medivir to present at the Pareto Securities´ Healthcare conference

Retrieved on: 
Thursday, September 1, 2022
Partnership, Patient, Medivir, Cancer, Nasdaq Stockholm, Drug development, Nasdaq, SMAC, Market capitalization, Pharmaceutical industry

STOCKHOLM, Sept. 1, 2022 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR)today announces that the company will present at the Pareto Securities Healthcare conference on September 7, 2022.

Key Points: 
  • STOCKHOLM, Sept. 1, 2022 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR)today announces that the company will present at the Pareto Securities Healthcare conference on September 7, 2022.
  • CEO Jens Lindberg will present the company and the clinical development of the focus project fostroxacitabine bralpamide (fostrox) in primary liver cancer.
  • Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high.
  • Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership.

Medivir to present at the Erik Penser Bank Company Day

Retrieved on: 
Tuesday, August 23, 2022
Market capitalization, Partnership, Patient, Medivir, Cancer, Nasdaq Stockholm, Drug development, NASDAQ, SMAC, Trial of the century, Pharmaceutical industry

STOCKHOLM, Aug. 23, 2022 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR)today announces that the company will present at the Erik Penser Bank Company Day on August 24, 2022.

Key Points: 
  • STOCKHOLM, Aug. 23, 2022 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR)today announces that the company will present at the Erik Penser Bank Company Day on August 24, 2022.
  • CEO Jens Lindberg will present the company and its plan for the ongoing clinical study with fostroxacitabine bralpamide (fostrox).
  • Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high.
  • Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership.

Saturn Oil & Gas Inc. Announces Successful Drilling Results at Oxbow Asset and Increases 2022 Guidance

Retrieved on: 
Monday, May 16, 2022
Interest, Income, CAD, NGL, Company, EBITDA, Bas, Natural gas, OPEC, Depreciation, SMKA, EUR, PP, News, TSX Venture Exchange, Public expenditure, West Texas Intermediate, Tax, Health, Estimated ultimate recovery, Natural-gas condensate, Transport, USD, COVID-19, Legislation, Media contacts database, Culture, AECO, Industry, MSW, Frankfurt Stock Exchange, Abbreviation, Heat, E&E, EV, Safety, Ovintiv, Maintenance, IFRS, Market capitalization, Ratio, Acquisition, Collection, PP&E, ESG, Oil, Bank, Kerosene, Real estate, Bookkeeping, Risk management, Adjustment

(2) Based on a Q4 2022 revised forecast average production range of 8,500 to 8,900 boe/d, 95% crude oil and NGL production.

Key Points: 
  • (2) Based on a Q4 2022 revised forecast average production range of 8,500 to 8,900 boe/d, 95% crude oil and NGL production.
  • (6) Enterprise Value (EV) based on the $2.65 share price and 32.4 million basic shares plus forecast 2022 year end net debt.
  • About Saturn Oil & Gas Inc.
    Saturn Oil & Gas Inc. is a growing Canadian energy company focused on generating positive shareholder returns through the continued responsible development of high-quality, light oil weighted assets, supported by an acquisition strategy that targets highly accretive, complementary opportunities.
  • Saturn Oil & Gas Investor & Media Contacts:
    This news release includes non-GAAP financial measures and ratios as further described herein.

Medivir to present at the Redeye Orphan Drugs Conference

Retrieved on: 
Monday, April 25, 2022
Conference, Drug development, Market capitalization, Nasdaq Stockholm, Partnership, Nasdaq, SMAC, Patient, Cancer, Pharmaceutical industry, Medivir

STOCKHOLM, April 25, 2022 /PRNewswire/ --Medivir AB (Nasdaq Stockholm: MVIR)today announces that the company will present at the Redeye Orphan Drugs Conference on April 27, 2022.

Key Points: 
  • STOCKHOLM, April 25, 2022 /PRNewswire/ --Medivir AB (Nasdaq Stockholm: MVIR)today announces that the company will present at the Redeye Orphan Drugs Conference on April 27, 2022.
  • The presentation is live broadcasted and can be followed at;
    Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high.
  • Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a pro-drug designed to selectively treat liver cancer cells and to minimize side effects.
  • Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership.

Medivir to participate at the Kempen Life Sciences Conference

Retrieved on: 
Tuesday, April 19, 2022
Conference, Drug development, Market capitalization, Nasdaq Stockholm, Partnership, Nasdaq, SMAC, Patient, Cancer, Pharmaceutical industry, Medivir

STOCKHOLM, Sweden, April 19, 2022 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR)today announces that the company will participate at the Kempen Life Sciences Conference, April 21.

Key Points: 
  • STOCKHOLM, Sweden, April 19, 2022 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR)today announces that the company will participate at the Kempen Life Sciences Conference, April 21.
  • More information about the event is available at the organizer's website: https://www.kempen.com/en/securities/events/life-sciences-conference
    Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high.
  • Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a pro-drug designed to selectively treat liver cancer cells and to minimize side effects.
  • Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership.

Cipher Pharmaceuticals Announces Partner, Moberg Pharma's Regulatory Submission to FDA for North American Phase 3 Study

Retrieved on: 
Tuesday, March 22, 2022
Adoption, Market capitalization, Company, Interim, Moberg, OMX, Marketing, Terbinafine, Substance-related disorder, Coronavirus, Compliance, Risk, Hospital, CDN, Privacy, Food, Onychomycosis, TSX, Nasdaq Stockholm, Industry, Goal, Hope, COVID-19, Regulation of tobacco by the U.S. Food and Drug Administration, Intellectual property, CRO, CPH, FDA, Insurance, Acquisition, Patient, Partnership, Pharmaceutical industry, Fine chemical, IQVIA

The randomized, multicenter, vehicle-controlled Phase 3 study will include approximately 350 patients in North America.

Key Points: 
  • The randomized, multicenter, vehicle-controlled Phase 3 study will include approximately 350 patients in North America.
  • The study design builds on the experience gained from the previous Phase 3 studies.
  • Moberg Pharma will cooperate with the same CRO, lead investigator and successful sites from the previous North American study.
  • "We are pleased to see the continued progress that Moberg is making to commercialize MOB-015," said Craig Mull, Interim CEO of Cipher.

Shift4 Payments Announces Results of Consent Solicitation Relating to its 4.625% Senior Notes Due 2026

Retrieved on: 
Thursday, March 17, 2022
Professional Services, Technology, Other Technology, Mobile, Wireless, Finance, Internet, Banking, Company, Surety, Amendment, NYSE, Consent, National Association, Market capitalization, Industry, Time, Debt-to-GDP ratio, Trustee, Commerce Bank & Trust Company, Life insurance, Note

The Company expects the Consent Payment to be paid on March 18, 2022.

Key Points: 
  • The Company expects the Consent Payment to be paid on March 18, 2022.
  • Pursuant to the terms of the Supplemental Indenture, the Amendment became effective at the Effective Time, and binds every holder of Notes.
  • Shift4 (NYSE: FOUR) is boldly redefining commerce by simplifying complex payments ecosystems across the world.
  • As the leader in commerce-enabling technology, Shift4 powers billions of transactions annually for hundreds of thousands of businesses in virtually every industry.

MContent in Collaboration with PwC Announce Their Arrival in the Metaverse with Their Cineverse Experience

Retrieved on: 
Saturday, February 26, 2022
Metaverse, Company, PricewaterhouseCoopers, Investment, World Bank, GCC, Lubricant, Ecosystem, NFT, Technology, Alfa Romeo, Founder CEO, Market capitalization, SEC, Mercedes-Benz, GAC, Blockchain, CEO, XR, Non-fungible token, Cryptocurrency, Anwar Gargash, Virtual reality, VR, AR, Augmented reality, Television, Video game, Sandbox, Cinema

200 high profile guests were invited to a film premiere at the Beach - in the Metaverse

Key Points: 
  • Designed to convert content viewers into content owners, the first-of-its-kind platform enables crowd funding of film production and capital-intensive content creators using Cryptocurrency, NFTs and the Cineverse.
  • Speaking at the event, Umair Masoom, Founder & CEO of MContent, said, "The immersive cinema experience - designed in collaboration with PwC and showcased to our guests today has global scalability & mass adoption capability.
  • By bringing the Cineverse to a global audience, MContent wants to increase funding & screening opportunities for thousands of independent film makers globally.
  • PwC refers to the PwC network and/or one or more of its member firms, each of which is a separate legal entity.

PwC and MContent Announce Their Collaboration with an Experience of the Cineverse to the World

Retrieved on: 
Friday, February 25, 2022
Metaverse, Company, PricewaterhouseCoopers, Television in the Netherlands, Investment, World Bank, GCC, Lubricant, Ecosystem, NFT, Alfa Romeo, Market capitalization, SEC, Mercedes-Benz, GAC, Blockchain, Partner, CEO, XR, Non-fungible token, Cryptocurrency, Anwar Gargash, Technology, Virtual reality, VR, AR, Augmented reality, Video game, Sandbox, Cinema

200 high profile guests were invited to a film premiere at the Beach - in the Metaverse

Key Points: 
  • Designed to convert content viewers into content owners, the first-of-its-kind platform enables crowd funding of film production and capital-intensive content creators using Cryptocurrency, NFTs and the Cineverse.
  • Speaking at the event, Umair Masoom, Founder and CEO of MContent, said, "The immersive cinema experience - designed in collaboration with PwC and showcased to our guests today has global scalability and mass adoption capability.
  • By bringing the Cineverse to a global audience, MContent wants to increase funding and screening opportunities for thousands of independent film makers globally.
  • PwC refers to the PwC network and/or one or more of its member firms, each of which is a separate legal entity.

PLATINUM EQUITY PORTFOLIO COMPANY L&R DISTRIBUTORS ACQUIRES SJ CREATIONS

Retrieved on: 
Friday, March 4, 2022
Auctus, SJ, Leadership, Stock, Beauty, Market capitalization, S. "Sundi" Sundaresh, CA, COVID-19, Acquisition, National, O'Melveny & Myers, Marketing, Telecommunication, Platinum Equity, State, Platinum, Technology, Attitude, R, LR, Health, William Wells (general), Transport, PNC Financial Services, Financial services, Retail, Renewable energy, Distribution (marketing), Bookkeeping, Supermarket, Region

LOS ANGELES and BROOKLYN, N.Y., March 4, 2022 /PRNewswire/ -- Platinum Equity portfolio company L&R Distributors announced today the acquisition of SJ Creations ("SJ") from the company's founders.  Financial terms were not disclosed.

Key Points: 
  • LOS ANGELES and BROOKLYN, N.Y., March 4, 2022 /PRNewswire/ --Platinum Equity portfolio company L&R Distributors announced today the acquisition of SJ Creations ("SJ") from the company's founders.
  • SJ Creations founders Sundi and Rich Yousko will remain involved with the business going forward.
  • L&R CEO Marc Bodner said SJ Creations is a great fit for L&R.
  • The SJ Creations acquisition represents the 12th buy-side transaction Platinum Equity's Small Cap team has completed in the last twelve months.